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Hematologic relapse after an allogeneic hemopoietic stem cell transplant (HSCT) in patients with acute leukemia is associated with a poor outcome, despite further cell therapy in the form of donor lymphocyte infusions (DLI). 1 This has been taken as evidence that acute leukemia is less sensitive to the so called graft versus leukemia (GvL) effect, especially if compared with chronic myeloid leukemia (CML), in which DLI alone can induce durable long term molecular remissions. 2 However, several reports suggest a strong protection exerted by chronic graft versus host disease (GvHD) in acute lymphoid (ALL) and myeloid (AML) leukemia, 3, 4 and low dose immunosuppression in the first days after transplant also reduces the risk of relapse. 5, 6 Perhaps DLI would be effective in ALL and AML patients, if given when the tumor burden is low. Attempts to monitor minimal residual disease (MRD) in acute leukemia post-HSCT have been reported and seem to predict hematologic relapse. 7, 8 Some of these patients were given immune intervention to prevent hematologic relapse. 9 In this study we wished to assess (a) the predictive value of MRD on hematologic relapse post-transplant in AML/ALL patients and (b) whether cellular therapy with DLI would protect against leukemia relapse. We studied 80 patients with ALL (n=44) or AML (n=36), undergoing an allogeneic hemopoietic stem cell transplant. MRD was evaluated monthly, on bone marrow samples using a qualitative nested polymerase chain reaction (PCR) for IgH VDJ , as previously described, 10 and TCR gene rearrangement for T-ALL. Real time PCR for Wilms Tumour (WT1) expression was used in AML. 11 MRD was considered positive in AML when WT1 copy numbers every 104 copies of Abl were superior to 180. Molecular positivity was defined as a positive PCR assay, in the presence of a marrow sample in hematologic remission (blast count < 5%).
The cumulative incidence of MRD positivity was 45%, with a median interval from transplant to first MRD positivity of 120 days, and from transplant to hematologic relapse of 203 days. Hematologic relapse was significantly higher in MRD+ patients (36%) as compared to MRD-patients (16%), p=0.03). Patients were analyzed according to whether they were always MRD-(n=44), MRD+ receiving DLI (MRD+DLI+) (n=17) or MRD+ non receiving DLI (MRD+DLI-) (n=19). Reasons for not giving DLI were presence or development of GvHD after cessation of immunosuppressive therapy (n=7), donor unavailable (n=8), early relapse (n=2), other (n=2). Hematologic relapse was 16% in MRD-patients, 6% in MRD+DLI+ patients and 63% in MRD+DLI-patients (p<0.0001); the actuarial 3 year survival in these three groups was 78%, 80% and 26% (p=0.001) . Mortality due to acute GvHD following DLI was 12%. In multivariate COX analysis, MRD group predicted relapse (p<0.0001) and survival (p=0.01), together with disease phase and chronic graft versus host disease. In MRD+ patients, DLI protected against relapse (p=0.003) and improved survival (p=0.01).
In conclusion, we confirm that minimal residual disease detected post-transplant is a significant predictor of relapse. Treatment of MRD with donor lymphocyte infusions, appears to protect against leukemia relapse, although caution with DLI dosing, needs to be used, because of the potential risk of graft versus host disease. 
Resumo

A doença residual mínima (DRM) foi monitorada em 80 pacientes com leucemia linfóide aguda (n=44) e mielóide aguda (n=36) que foram submetidos ao transplante alogênico de célula-tronco. Marcadores da DRM foram a IgH
